Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage with a target price of 60.67 CNY per share [1]. Core Views - The company is positioned as a leader in the high-end ophthalmic medical device market, with a strong focus on innovation and a comprehensive product matrix that supports growth in various segments, including surgical treatment, myopia control, and vision care [6][10]. - The approval of the "Longjing® PR" intraocular lens in January 2025 is expected to break the import monopoly and enhance the company's competitive edge in the high-end artificial lens market [6][27]. - The increasing demand for ophthalmic treatments driven by an aging population and rising consumer spending is anticipated to accelerate the domestic replacement of imported products [6][34]. Summary by Sections 1. Innovation and Market Position - The company has been deeply engaged in the ophthalmic device sector since its establishment in 2010, becoming a key player in the high-end refractive intraocular lens market [10]. - The product range includes high-end artificial lenses for cataract surgery and myopia control, with significant market penetration achieved through strategic expansions and acquisitions [10][16]. 2. Financial Performance - Revenue projections show a steady increase from 951 million CNY in 2023 to 2,118 million CNY by 2027, with a year-on-year growth rate of 64.1% in 2023 and 48.2% in 2024 [5]. - Net profit is expected to grow from 304 million CNY in 2023 to 563 million CNY by 2027, reflecting a compound annual growth rate of 21.8% [5]. 3. Product Matrix and Growth Drivers - The company’s artificial lens segment is the highest revenue contributor, accounting for 43.86% of total revenue in the first half of 2025, followed by contact lenses at 30.06% [18]. - The introduction of the "Longjing® PR" lens is expected to significantly enhance the product offering and cater to the growing demand for high-quality vision correction solutions [27][34]. 4. Market Trends and Opportunities - The aging population in China is projected to increase the number of cataract patients, thereby expanding the market for high-end artificial lenses [34]. - The company is also capitalizing on the growing myopia prevention market, with its "Punotong®" orthokeratology lenses gaining traction under national health initiatives [47]. 5. Competitive Landscape - The company has established a strong competitive position through its innovative product offerings and strategic acquisitions, which have allowed it to build a comprehensive product line that meets diverse consumer needs [6][10]. - The recent approval of its products underlines the company's commitment to innovation and its ability to compete effectively against established international brands [27][34].

Investment Rating - The industry investment rating is "Outperform the Market" [29] Core Insights - AbbVie reported a total revenue of $44.542 billion for the first three quarters of 2025, representing an 8.0% year-over-year growth, with Q3 revenue reaching $15.776 billion, up 9.1% [5][9] - The strong performance is primarily driven by two key immunology drugs, Rinvoq and Skyrizi, which have seen significant sales growth [5][19] - AbbVie has raised its full-year guidance, indicating positive momentum across its business segments, including immunology, neuroscience, and oncology [5][9] Summary by Sections Part 1: Financial Overview and Key Events - AbbVie’s revenue contributions from major segments include Immunology at $21.780 billion (+12.3%), Neuroscience at $7.806 billion (+20.3%), and Oncology at $4.991 billion (+2.6%) for the first three quarters of 2025 [5][9] - The company has advanced several projects into regulatory approval and submission phases, including Rinvoq for various indications [10][12][23] Part 2: Core Product Sales Analysis - Rinvoq generated $5.930 billion in revenue for the first three quarters of 2025, a 43.3% increase, while Skyrizi achieved $12.556 billion, growing 58.1% [19][17] - The combined sales of Rinvoq and Skyrizi reached $6.9 billion in Q3 alone, establishing them as leading products in the immunology sector [19][27] Part 3: Future Pipeline Milestones - In 2026, AbbVie anticipates five drug approvals, four regulatory submissions, and five Phase III data readouts, including Rinvoq for vitiligo and alopecia areata [22][23] - Key upcoming regulatory events include submissions for Tavapadon for Parkinson's disease and Venclexta for higher-risk MDS [22][23] Part 4: Investment Recommendations - The strong sales of Skyrizi and Rinvoq are expected to continue driving AbbVie's growth, with Skyrizi projected to become a "super blockbuster" in 2024 [27] - Investors are advised to monitor domestic companies targeting the IL-23 pathway, such as Innovent Biologics and Kintor Pharmaceutical [27]

Investment Rating - The report maintains a "Strong Buy" rating for the industry [1] Core Insights - The evolution of intelligent driving has entered the AI 2.0 phase, focusing on scalable capabilities and the ability to autonomously handle extreme edge scenarios, which will further enhance the commercial viability of intelligent driving systems [1] - Major players in the high-level intelligent driving sector are accelerating their entry into the Robotaxi business, leveraging mass-produced vehicles to optimize model training and performance in extreme scenarios [1][79] - The report highlights the importance of diverse real-world data and robust R&D resources as key competitive advantages for players in the AI driving space [81] Summary by Sections 1. Tesla's Software and Hardware Iterations - Tesla's FSD (Full Self-Driving) software has achieved significant milestones, with over 60 billion miles driven cumulatively, showcasing its leading position in intelligent driving [7] - The next-generation AI5 chip is expected to greatly enhance the performance and energy efficiency of Tesla's driving systems [8][9] 2. Development Stages of High-Level Intelligent Driving in China - The industry has transitioned from a rule-based system to a fully data-driven approach, marking the arrival of the AI driving era [15][12] - The current phase emphasizes end-to-end models that utilize extensive data for improved driving performance and user experience [18][19] 3. Technical Architecture: Mainstream Player Directions - The VLA (Vision-Language-Action) model integrates visual, language, and action modalities, enhancing the system's ability to understand and interact with the physical world [27][28] - Huawei's ADS 4.0 emphasizes a scene-driven approach, utilizing cloud simulations to train AI drivers without relying on large language models [49][50] 4. Business Model: Acceleration of Robotaxi Initiatives - The Robotaxi business is seen as a critical avenue for data collection and model optimization, with major players planning to leverage mass-produced vehicles for this purpose [65][66] - The report outlines two main technological routes for Robotaxi operations: the "crossing route" represented by Waymo and the "gradual route" represented by Tesla, each with its own advantages and challenges [67][68] 5. Investment Recommendations - The report recommends investing in companies such as Seres, Horizon Robotics, Great Wall Motors, Li Auto, and Xpeng Motors, which are well-positioned to capitalize on the advancements in AI driving technology [81]

Core Insights - The Federal Reserve's interest rate cut expectations have fluctuated significantly, leading to a decline in risk assets and a slight strengthening of the US dollar. The MSCI global index fell by 2.5%, with major developed market indices also declining, particularly the Dow, S&P, Nasdaq, and Hang Seng [2][33] - The US labor market showed improvement in September, with non-farm payrolls increasing by 119,000, but the unemployment rate unexpectedly rose to 4.4% due to a higher labor participation rate. The government announced that October's non-farm data would not be released, with some data to be combined with November's figures in December [3][4][6] - The internal divisions within the Federal Reserve have intensified, causing significant volatility in interest rate cut expectations. The minutes from the October FOMC meeting indicated that many officials preferred to maintain rates, leading to a 20 percentage point drop in market expectations for a rate cut to 30%. However, comments from New York Fed President Williams suggested potential adjustments, causing expectations to rise to 71% [7][9] Economic Outlook - The US economy is expected to experience moderate growth in 2026, supported by resilient technology investments and stable consumer spending. AI investments are projected to remain strong, driven by commitments from countries like Japan and South Korea to invest in US AI infrastructure [12][17] - The labor market is anticipated to maintain a balance between supply and demand, with the unemployment rate expected to hover around 4.5% throughout 2026. The impact of tariffs on inflation is expected to diminish in the second half of the year, contributing to a more favorable economic outlook [17][16] Market Performance - The US stock market is currently in a phase of consolidation following previous high valuations, with limited further downside potential. Sectors with low valuations and solid earnings support, such as healthcare and utilities, are expected to show resilience [2][33] - The S&P 500 index's price-to-earnings ratio (TTM) stands at 28.09, slightly below the past ten-year average plus one standard deviation, indicating a relatively high valuation level. The index's equity-to-bond ratio is at 0.87, above the historical average minus one standard deviation [43][39] Sector Analysis - The technology sector is likely to continue driving growth, with major tech companies expected to maintain high capital expenditure growth rates. This is supported by favorable policies and a stable economic environment [12][28] - The healthcare and consumer sectors are projected to remain resilient amid changing market conditions, with potential for growth driven by stable consumer spending and investment in technology [2][12]

Investment Rating - The report maintains a "Strong Buy" rating for the industry, indicating a positive outlook for investment opportunities [1]. Core Insights - The report highlights the expansion of floating offshore wind enterprises and the implementation of mandatory grid connection capabilities for large-scale energy storage in Europe, signaling a shift towards more advanced renewable energy technologies [5][6]. Summary by Sections Wind Power - Recent developments include the commencement of the deep-sea mooring equipment project by Yaxing Anchor Chain, which indicates accelerated commercialization of floating offshore wind [5][10]. - The domestic floating wind turbine prototypes have transitioned to capacities of 20MW and above, with notable projects from State Power Investment Corporation and Mingyang Smart Energy [5][10]. - The UK government has allocated £180 million for floating offshore wind projects, suggesting a robust international market for floating wind technology [5][10]. - The wind power index fell by 6.88%, underperforming the CSI 300 index by 3.11 percentage points, with a current PE_TTM valuation of approximately 24.12 times [4][11]. Photovoltaics - Longi Green Energy has signed an investment agreement for a green methanol project, aiming for completion by Q3 2027, which is expected to diversify its revenue streams amid competitive pressures in the photovoltaic sector [5][6]. - The photovoltaic equipment index decreased by 12.26%, with the current PE_TTM valuation around 44.19 times, reflecting ongoing challenges in the market [4][11]. Energy Storage & Hydrogen - The European Network of Transmission System Operators for Electricity (ENTSO-E) has mandated that large-scale battery storage systems over 1MW must have grid connection capabilities, addressing the declining inertia in the grid due to increased renewable energy penetration [6][10]. - The energy storage index dropped by 11.6%, with a PE_TTM of 29.85 times, while the hydrogen index decreased by 8.24%, with a PE_TTM of 33.36 times [4][11]. - Chinese energy storage companies have secured over 40GWh of orders in Europe, indicating a strong market presence and technological advantage [6][10]. Investment Recommendations - For wind power, companies like Goldwind Technology, Mingyang Smart Energy, and Yunda Co. are recommended due to their stable pricing and expansion into overseas markets [6]. - In photovoltaics, companies such as Dier Laser, Aiko Solar, and Longi Green Energy are highlighted for their potential amidst structural opportunities [6]. - In energy storage, Sunshine Power and Haibo Technology are recommended for their competitive advantages in the global market [6].

Investment Rating - The report gives a "Recommended" rating for Huaxia Eye Hospital (301267.SZ) [1] Core Views - The demand for ophthalmic diagnosis and treatment is continuously growing, supported by favorable national policies for the development of private specialty hospitals. The number of myopia patients in China has increased from 540 million in 2016 to 660 million in 2020, with the incidence rate rising from 39.2% to 47.1% [6][24] - The company is successfully expanding its operations, with a decrease in the revenue contribution from its core hospital, Xiamen Eye Center, indicating successful new hospital openings and improved performance from other facilities [6][40] - The profitability of cataract and refractive surgery projects is recovering, with revenue growth in refractive services driven by technological upgrades [6][34] Summary by Sections 1. Company Overview - Huaxia Eye Hospital focuses on ophthalmic medical services and has expanded its chain operations nationwide, establishing a network of 64 specialized hospitals and 67 vision centers across 49 cities [9][15] 2. Market Demand and Policy Support - The demand for eye care services is on the rise, with significant growth in the elderly population and increasing awareness of eye health among the public. The aging population is expected to drive the demand for cataract surgeries and other eye-related treatments [24][26] - National policies are favorable for the development of private specialty hospitals, enhancing the overall healthcare service quality and expanding the market for ophthalmic services [29][30] 3. Business Segments Performance - The refractive surgery segment is the company's core business, contributing the highest revenue share and showing a recovery in profit margins due to new surgical techniques [18][34] - The cataract business faced short-term pressure due to national procurement policies but is expected to stabilize and grow in the long term as the aging population increases [31][43] - The integrated vision care project has shown steady revenue growth, although initial investments in new centers have impacted profit margins [38] 4. Financial Performance and Forecast - The company achieved a revenue of 40.13 billion yuan in 2023, with a year-on-year growth of 24.1%. However, growth slowed in 2024 due to high base effects, with revenue of 40.27 billion yuan, a mere 0.3% increase [5][20] - Profit forecasts for 2025, 2026, and 2027 are 4.82 billion yuan, 5.52 billion yuan, and 6.29 billion yuan respectively, indicating a positive outlook for sustained growth [6][43]

Investment Rating - Industry investment rating is "Outperform the Market" [23] Core Viewpoints - Nvidia's Q3 2026 financial report shows impressive performance with revenue of $57 billion, a year-on-year increase of 62% and a quarter-on-quarter increase of 22%. The net profit reached $31.9 billion, growing 65% year-on-year and 21% quarter-on-quarter. The outlook for Q4 anticipates revenue of $65 billion, indicating a year-on-year growth of 65% and a quarter-on-quarter growth of 14%, reflecting strong global demand for AI computing power [5][10][19] - The competition in the global AI large model sector remains intense, which is expected to drive the application of large models and sustain high demand in the AI computing market. Domestic large models in China are continuously iterating and improving, positioning themselves among the top tier globally [19][22] Summary by Sections Industry News and Commentary - Nvidia's Q3 2026 report highlights a robust demand for AI computing power, with significant revenue growth driven by the data center business, which generated $51.2 billion, a 66% increase year-on-year and a 25% increase quarter-on-quarter. The gaming and professional visualization segments also showed strong performance [9][10][19] - The overall computer industry index fell by 2.74% this week, while the CSI 300 index dropped by 3.77%, indicating that the computer sector outperformed the broader market by 1.03 percentage points [13][16] Investment Recommendations - The report suggests focusing on investment opportunities in the AI sector, particularly in AI computing power and algorithms. Recommended stocks include Haiguang Information, Longxin Zhongke, and Industrial Fulian for AI computing power, and strong recommendations for companies like Hengsheng Electronics and Zhongke Chuangda in AI algorithms and applications [19][22]

证券研究报告 强生口服IL-23拮抗剂申报上市，启动与乌司奴单抗的头 对头研究 生物医药行业 强于大市（维持） 平安证券研究所生物医药团队 分析师： 叶寅投资咨询资格编号:S1060514100001邮箱：YEYIN757@PINGAN.COM.CN 倪亦道投资咨询资格编号:S1060518070001邮箱：NIYIDAO242@PINGAN.COM.CN 韩盟盟投资咨询资格编号:S1060519060002邮箱：HANMENGMENG005@PINGAN.COM.CN 裴晓鹏投资咨询资格编号:S1060523090002邮箱：PEIXIAOPENG719@PINGAN.COM.CN 何敏秀投资咨询资格编号:S1060524030001邮箱：HEMINXIU894@PINGAN.COM.CN 王钰畅投资咨询资格编号:S1060524090001邮箱：WANGYUCHANG804@PINGAN.COM.CN 曹艳凯投资咨询资格编号:S1060524120001邮箱：CAOYANKAI947@PINGAN.COM.CN 张梦鸽投资咨询资格编号:S1060525070003邮箱：ZHANGMENGGE752@PIN ...

Industrial Sector - Steel and building materials production has rebounded, while the operating rate of float glass has decreased[2] - The apparent demand for steel building materials has increased, while the operating rate for the textile polyester sector has shown seasonal weakness[2] - The operating rates for automotive tires have slightly declined this week[2] Real Estate - New home sales in 30 major cities decreased by 20.8% year-on-year, but the growth rate improved by 8.7 percentage points compared to last week[2] - The second-hand housing listing price index fell by 0.98% week-on-week, indicating a slight narrowing of the decline[2] Domestic Demand - Movie box office revenue increased by 74.7% year-on-year, with a daily average of 83.89 million yuan[2] - The volume of postal express deliveries has grown by 8.3% year-on-year, showing recovery in logistics[2] - Retail sales of major home appliances decreased by 34.6% year-on-year, a decline of 7.2 percentage points compared to the previous value[2] External Demand - Port cargo throughput increased by 3.4% year-on-year, while container throughput rose by 7.4%[2] - The export container freight index rose by 2.6% week-on-week, indicating a slight increase in shipping costs[2] Prices - The agricultural product wholesale price index fell by 0.1% week-on-week, reflecting seasonal trends[2] - The industrial product prices weakened, with the South China industrial product index dropping by 1.9%[2]

证券研究报告 金融行业周报 ——银行盈利修复，监管发布养老预收费存管指引 证券分析师 王维逸S1060520040001（证券投资咨询） 袁喆奇S1060520080003（证券投资咨询） 李冰婷S1060520040002（证券投资咨询） 许 淼S1060525020001（证券投资咨询） 研究助理 李灵琇S1060124070021（一般证券业务） 3、12 部门联合印发《金融支持北京市提振扩大消费实施方案》。11月18日，中国人民银行北京市分行等12部门联合印 发《关于金融支持北京市提振和扩大消费的实施方案》。二十届四中全会指出，要大力提振消费、深入实施提振消费专 项行动。《实施方案》的提出有助于贯彻落实这一重要决策部署：它覆盖了商品消费、文旅体育等多领域及重点群体， 金融支持手段多元且贴合北京城市特色，既注重扩大消费供给，又着力优化消费环境，将有效撬动金融资源赋能消费提 振，为提振扩大消费提供坚实支撑。 2 2 CONTENT 目录 重点聚焦 请务必阅读正文后免责条款 2025年11月23日 1 核心观点 银行盈利修复，监管发布养老预收费存管指引 1、银行盈利修复，息差边际企稳。11月14日，国家金融 ...